Clover Biopharmaceuticals (Clover) reported a sharp earnings turnaround for the six months ended 30 June 2026, booking net profit of RMB0.95 billion versus a RMB0.10 billion loss a year earlier. The swing was primarily driven by a non-recurring settlement gain of RMB1.09 billion related to the Global Alliance for Vaccines and Immunisation (GAVI).
Revenue and expenses • Revenue declined to RMB0.18 million (H1 2025: RMB3.25 million) after the wind-down of AdimFlu-S commercial activities in mainland China.
• Research and development spending rose 26.0 % year on year to RMB104.84 million, reflecting continued investment in the company’s respiratory vaccine pipeline.
• Selling and distribution costs fell to RMB1.10 million (H1 2025: RMB4.91 million) following the product withdrawal.
• Administrative expenses edged up 5.3 % to RMB30.73 million, mainly on higher consulting fees, partially offset by cost-saving measures.
• Other expenses reached RMB20.32 million, largely comprising inventory write-downs and impairment of packaging-service prepayments.
Adjusted performance Excluding RMB6.78 million in share-based compensation, adjusted profit totalled RMB0.96 billion, versus an adjusted loss of RMB97.64 million in the prior-year period.
Balance-sheet highlights • Cash and bank balances fell to RMB90.54 million at end-June (31 December 2025: RMB271.40 million) after the upfront cash payment to GAVI and ongoing R&D outlays.
• The GAVI settlement created a liability of RMB395.03 million, with RMB374.60 million classified as non-current.
• Non-current trade payables of RMB485.67 million are owed to the Coalition for Epidemic Preparedness Innovations (CEPI) following assignment of Dynavax adjuvant payables.
• Total liabilities stood at RMB1.04 billion, leaving net liabilities of RMB0.80 billion. The group had no bank borrowings.
R&D and pipeline progress During the reporting period Clover: 1. Advanced Phase II trials in Australia for RSV + hMPV ± PIV3 combination vaccines (SCB-1022/1033) targeting up to 420 older adults, with initial data expected Q3 2026. 2. Released additional positive U.S. Phase I re-vaccination data for RSV candidate SCB-1019 versus GSK’s Arexvy. 3. Continued Phase Ib evaluation of thrombocytopenia therapy SCB-219M. 4. Maintained Chinese EUA for COVID-19 vaccine SCB-2019.
Investments and capital commitments • Held US$2.09 million (RMB14.25 million) in Blue Ocean Wealth Flexible Allocation Plan, approximating 6 % of total assets; full redemption completed post-period in August 2026. • Capital commitments remained at RMB6.60 million. • No dividends declared and no treasury-share activity during the period.
Outlook Management will prioritise resources on the respiratory vaccine franchise, pursue cost discipline, and explore financing, licensing and partnership opportunities to support longer-term growth and liquidity needs.
Comments